Abstract |
Chronic lymphocytic leukemia cell (CLL) usually (95%) express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells. However, among B CLL, 7 to 20% do not express CD5. The significance of the lack of CD5 expression remains unclear. We reviewed 42 consecutive CD5- B CLL seen in three French medical centers from 1985 to 1991 and compared them with 79 CD5+ B CLL. Immunophenotype studies were performed using indirect immunofluorescence under light microscopy as well as flow cytometry after 1988. B CLL was considered to be CD5 negative when less than 5% of mononuclear cells expressed CD5 after subtraction of the number of T-cells. Cases with CD5- B CLL had isolated splenomegaly more frequently (p = 2.10(-7)). They frequently expressed a higher level of surface immunoglobulin (S-Ig) or the switch mu/delta phenotype (p = 4.7 10(-2)). The median survival time was not reached but no significant difference between CD5 negative and positive B CLL was observed at the time of our data analysis (p = 0.97). Clinical presentation of CD5- B CLL seems to be different from other forms of B CLL. Although, no conclusion can be reached in terms of prognosis, CLL with low expression of CD5 should be regarded as a subtype of CLL with a different clinical presentation than CD5+ CLL.
|
Authors | G Cartron, C Linassier, J L Bremond, B Desablens, M T Georget, B Fimbel, F Luthier, J L Dutel, J P Lamagnere, P Colombat |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 31
Issue 1-2
Pg. 209-16
(Sep 1998)
ISSN: 1042-8194 [Print] United States |
PMID | 9720730
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- CD5 Antigens
(blood)
- Female
- France
(epidemiology)
- Humans
- Immunophenotyping
- Incidence
- Leukemia, Lymphocytic, Chronic, B-Cell
(epidemiology, immunology, mortality)
- Male
- Middle Aged
- Prognosis
- Retrospective Studies
- Survival Rate
|